Corporate Update, August 2025

Core Insights - Psyence BioMed is advancing its mission to develop safe and effective psychedelic therapies for mental health challenges, with significant progress in clinical development, regulatory compliance, and strategic partnerships [2][11][14] Clinical Development - The company is executing a clinical trial in partnership with Southern Star Research, aiming to expand patient access and accelerate enrollment [3] - A Steering Committee has been established to guide the development of a study on psilocybin for Alcohol Use Disorder, with plans to conduct the study in South Africa [6] - The partnership with PsyLabs is crucial for the Ibogaine program, with successful production of a GMP-aligned Ibogaine Total Alkaloid extract [7][9] Financial Position - As of August 4, 2025, Psyence BioMed reported a strong cash balance of $11.4 million and no outstanding debt, positioning the company for growth opportunities [11] - The company regained compliance with Nasdaq listing requirements in June 2025, marking a significant milestone in its growth [12] Strategic Vision - The company aims to build a resilient biotechnology firm focused on nature-derived psychedelic therapies, with a commitment to long-term value creation [14][18] - Psyence BioMed is positioned to lead in ethical and scalable production of ibogaine, leveraging its unique sourcing capabilities in Africa [17] Market Outlook - The global market for psilocybin-assisted therapy is projected to grow from $1.5 billion in 2024 to $3.3 billion by 2031, driven by increasing acceptance of psychedelic therapies [27][18]